Drugs / Rifalazil
Rifalazil
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01631201 | Jul 2012 → Mar 2013 | chlamydia trachomatis infectious disease | ActivBiotics Pharma, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00385385 | Oct 2006 → Sep 2008 | cerebrovascular disorder, coronary artery disorder, peripheral vascular disease | ActivBiotics | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00251849 | Nov 2005 → Dec 2007 | intermittent vascular claudication | ActivBiotics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifalazil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00385385 ↗ |
| Known as | KRM-1648 | ChEMBL registry synonym — accepted as the source's own label CHEMBL236297 ↗ |
| Known as | Rifalazilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL236297 ↗ |
| Modality | Small molecule | — CHEMBL236297 ↗ |
| Route | Oral | “oral rifalazil (25 mg)” PMID 24798277 ↗ May 2014 |